EGFR and cancer: Epidermal growth factor receptor (EGFR), a transmembrane glycoprotein with tyrosine kinase activity is often aberrantly activated by mutation or overexpression in many human cancers.11 Over 60% of the NSCLC cases show EGFR overexpression, which is associated with poor prognosis of NSCLC.12, 13 Ligand‐activated EGFR leads to stimulation of intracellular cascades, such as the RAS/RAF/ERK and PI3K/AKT signaling pathways.